Scarica l'app Stockscreener
393.66
1.70%
-6.82
Dopo l'orario di chiusura:
393.66
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TMO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$400.48
Aprire:
$393.78
Volume 24 ore:
2.32M
Relative Volume:
0.98
Capitalizzazione di mercato:
$148.60B
Reddito:
$42.90B
Utile/perdita netta:
$6.52B
Rapporto P/E:
23.09
EPS:
17.05
Flusso di cassa netto:
$6.72B
1 W Prestazione:
-4.47%
1M Prestazione:
-8.80%
6M Prestazione:
-23.30%
1 anno Prestazione:
-32.71%
Intervallo 1D:
$390.66
$396.34
Intervallo di 1 settimana:
$390.66
$415.40
Portata 52W:
$390.50
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Nome
Thermo Fisher Scientific Inc
Settore
Industria
Telefono
(781) 622-1000
Indirizzo
168 THIRD AVENUE, WALTHAM, MA
Confronta TMO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
393.66 | 155.55B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
184.54 | 140.35B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
501.57 | 41.67B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
108.53 | 32.44B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
137.00 | 24.71B | 15.50B | 1.33B | 2.16B | 7.34 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-01 | Iniziato | Stephens | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-03-18 | Ripresa | Citigroup | Neutral |
| 2024-01-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-26 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-06 | Ripresa | Citigroup | Buy |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-07-19 | Reiterato | Robert W. Baird | Outperform |
| 2023-07-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Reiterato | Barclays | Overweight |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-27 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Ripresa | Barclays | Overweight |
| 2021-10-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-16 | Iniziato | The Benchmark Company | Buy |
| 2021-03-18 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-01-08 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-14 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-20 | Ripresa | JP Morgan | Overweight |
| 2020-07-15 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Reiterato | Needham | Buy |
| 2020-04-23 | Reiterato | Needham | Buy |
| 2020-01-31 | Reiterato | Needham | Buy |
| 2020-01-22 | Iniziato | Credit Suisse | Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-07-25 | Reiterato | Needham | Buy |
| 2019-07-16 | Downgrade | Needham | Strong Buy → Buy |
| 2019-05-30 | Iniziato | Wolfe Research | Outperform |
| 2019-05-23 | Reiterato | Needham | Strong Buy |
| 2019-04-22 | Reiterato | Needham | Strong Buy |
| 2019-04-16 | Reiterato | BofA/Merrill | Buy |
Mostra tutto
Thermo Fisher Scientific Inc Borsa (TMO) Ultime notizie
$1000 Invested In Thermo Fisher Scientific 10 Years Ago Would Be Worth This Much Today - Benzinga
Thermo Fisher introduces new narcotics analyzers - Wiley Analytical Science
Why Is Thermo Fisher (TMO) Down 6.1% Since Last Earnings Report? - Yahoo Finance
Thermo Fisher makes drug analyzer for law enforcement - The Business Journals
Thermo Fisher Scientific introduces next-generation TruNarc handheld narcotics analyzers - Police1
Cell and Tissue Preservation Market in 2025-2032 Detailed Study - openPR.com
Immune Cell Engineering Market Comprehensive Research Study - openPR.com
Thermo Fisher grants CEO performance-based stock units By Investing.com - Investing.com India
Thermo Fisher grants CEO performance-based stock units - Investing.com
Thermo Fisher Approves CEO’s $60M Stock Award - TipRanks
Thermo Fisher Scientific Grants 5-Year Performance-Based Restricted Stock Units To CEOSEC Filing - marketscreener.com
Thermo Fisher Scientific Introduces Next Generation TruNarc Handheld Narcotics Analyzers to Support Public Safety - BioSpace
Petri Dish: Thermo Fisher’s new partner; Waters buys California company - The Business Journals
Thermo Fisher Scientific Declares Quarterly DividendMay 21, 2025 - BioSpace
Thermo Fisher Scientific Keeps Quarterly Dividend at $0.43 a Share, Payable July 15 to Investors of Record June 13 - marketscreener.com
Thermo Fisher sets quarterly dividend at $0.43 per share - Investing.com
Thermo Fisher, Mirai Bio link up to advance and produce gene therapies - Fierce Pharma
Middleton approves resolution to support Thermo Fisher Scientific - WKOW
Mirai Bio Announces Strategic Collaboration with Thermo Fisher Scientific - marketscreener.com
Forensics and toxicologyIndustry Focus eBook - News-Medical
Mirai Bio Announces Partnership with Thermo Fisher Scientific to Accelerate Development of Genetic Medicines - PR Newswire
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 - MSN
Laboratory Clean Bench Market to See Stunning Growth with Esco, Thermo Fisher Scientific, Labconco - openPR.com
Middleton TIF exception created for Thermo Fisher Scientific - The Center Square
Thermo Fisher Scientific launches BSC with improved airflow and ergonomics - Cleanroom Technology
Antibody and Protein Labeling Kits Market Outlook, Trends, Growth and Opportunities | Exactitude Consultancy - GlobeNewswire Inc.
How Thermo Fisher’s KingFisher PlasmidPro crunches hours of plasmid Prep to 5 minutes hands-on - drugdiscoverytrends.com
Thermo Fisher no longer Massachusetts' most valuable company - NBC Boston
Market shift: Boston Scientific emerges as Massachusetts' most valuable public company - The Business Journals
DNA Synthesizer Market Key Players AnalysisThermo Fisher Scientific, Merck KGaA, Agilent Technologies - openPR.com
Are Wall Street Analysts Bullish on Thermo Fisher Scientific Stock? - MSN
Are Wall Street Analysts Bullish On Thermo Fisher Scientific Stock? - Barchart.com
Plant Tissue Culture Market in 2025 Detailed Study Analysis with - openPR.com
Karyotype Market Size, Growth Analysis 2031 by Key Vendors- - openPR.com
Thermo Fisher Scientific Inc (TMO) Stock Analysis: Exploring a 40.81% Potential Upside - DirectorsTalk Interviews
Third Point LLC Dissolves Share Stake In Meta, Thermo Fisher Scientific & Cuts Share Stake In Microsoft - marketscreener.com
Thermo Fisher Scientific (NYSE:TMO) Partners With Cybin For Phase 3 Depression Treatment - simplywall.st
Gas Chromatography Market 2025-2032: Top Trends & Growth Drivers | Thermo Fisher Scientific, Inc., CMC Instruments - openPR.com
Fund Update: Veritas Asset Management LLP added 305,893 shares of THERMO FISHER SCIENTIFIC ($TMO) to their portfolio - Nasdaq
July 18th Options Now Available For Thermo Fisher Scientific (TMO) - Nasdaq
CYBN Gains on Thermo Fisher Partnership for CYB003 Production - GuruFocus
Thermo Fisher Scientific introduces automated plasmid DNA purification kit - European Pharmaceutical Manufacturer
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 (CYBN:NYSE) - Seeking Alpha
Cybin Says Thermo Fisher Scientific to Offer US-Based Manufacturing for Its Depressive Disorder Program - marketscreener.com
Cybin Partners with Thermo Fisher for U.S. Manufacturing of CYB003 - TipRanks
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Man - GuruFocus
Cybin partners with Thermo Fisher for Phase 3 drug production - Investing.com Australia
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder | CYBN Stock News - GuruFocus
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
RPMI Media Market Top PlayersMerck KGaA, Thermo Fisher Scientific Inc, Biological Industries, Sigma-Aldrich. - openPR.com
Incentives to keep Thermo Fisher in Middleton pass Wisconsin Legislature - Wisconsin State Journal
Thermo Fisher Scientific Inc Azioni (TMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):